Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 18/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.79 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20095467 | 0.90 | NAMPT (0.78) | NAMPTCYP3A4CYP2C9HDAC3HDAC4 | |
| SCHEMBL22654247 | 0.90 | NAMPT (0.78) | NAMPTCYP3A4CYP2C9HDAC3HDAC4 | |
| Daporinad SCHEMBL156944 | 0.88 | NAMPT (1.00) | NAMPTCYP3A4CYP2C9HDAC3HDAC4 | |
| Daporinad SCHEMBL31181445 | 0.88 | NAMPT (1.00) | NAMPTCYP3A4CYP2C9HDAC3HDAC4 | |
| Daporinad SCHEMBL82367 | 0.88 | NAMPT (1.00) | NAMPTCYP3A4CYP2C9HDAC3HDAC4 | |
| Daporinad SCHEMBL29635857 | 0.88 | NAMPT (1.00) | NAMPTCYP3A4CYP2C9HDAC3HDAC4 | |
| Daporinad SCHEMBL82368 | 0.88 | NAMPT (1.00) | NAMPTCYP3A4CYP2C9HDAC3HDAC4 | |
| Daporinad SCHEMBL23924298 | 0.88 | NAMPT (0.98) | NAMPTCYP3A4CYP2C9HDAC3HDAC4 | |
| SCHEMBL3458354 | 0.88 | NAMPT (0.98) | NAMPTCYP3A4CYP2C9HDAC3HDAC4 | |
| SCHEMBL3458355 | 0.88 | NAMPT (0.98) | NAMPTCYP3A4CYP2C9HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240293554-A1 | QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES | SEAGEN INC (US) | 2024-09-05 | — | — | US | disclosed |
| US-11931414-B2 | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates | SEAGEN INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240016953-A1 | TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEAGEN INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240016953-A1 | TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEAGEN INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240016953-A1 | TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEAGEN INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-11638762-B2 | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors | SEAGEN INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-11638762-B2 | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors | SEAGEN INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-11638762-B2 | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors | SEAGEN INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-20200197524-A1 | QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES | SEATTLE GENETICS, INC. (US) | 2020-06-25 | — | — | US | disclosed |
| US-20200197524-A1 | QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES | SEATTLE GENETICS, INC. (US) | 2020-06-25 | — | — | US | disclosed |
| CN-110799217-A | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates | 西雅图基因公司 | 2020-02-14 | — | — | CN | disclosed |
| US-20190314519-A1 | TARGETED DELIVERY OF NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEATTLE GENETICS, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190314519-A1 | TARGETED DELIVERY OF NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEATTLE GENETICS, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| CN-109843334-A | The targeted delivery of nicotinamide adenine dinucleotide remedial pathway inhibitor | 西雅图基因公司 | 2019-06-04 | — | — | CN | disclosed |
| WO-2018075600-A1 | TARGETED DELIVERY OF NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEATTLE GENETICS, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11931414-B2 | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates | NAMPT, NNMT, NADK | NAMPT 1/4885CYP3A4 4804/4885CYP2C9 4269/4885 |
| US-20240016953-A1 | TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | NAMPT, NAPRT, NNMT | NAMPT 1/4885CYP3A4 4861/4885CYP2C9 4684/4885 |
| US-20200197524-A1 | QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES | NAMPT, NNMT, NADK | NAMPT 1/4885CYP3A4 4804/4885CYP2C9 4269/4885 |
| US-20240293554-A1 | QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES | NAMPT, NNMT, NADK | NAMPT 1/4885CYP3A4 4804/4885CYP2C9 4269/4885 |
| US-20190314519-A1 | TARGETED DELIVERY OF NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | NAMPT, NME4, NNMT | NAMPT 1/4885CYP3A4 4869/4885CYP2C9 4851/4885 |
| US-11638762-B2 | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors | NAMPT, NME4, NNMT | NAMPT 1/4885CYP3A4 4869/4885CYP2C9 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.